Humacyte (HUMA) Competitors $4.54 +0.09 (+2.02%) (As of 09:03 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HUMA vs. MIRM, AMPH, JANX, APGE, RXRX, HRMY, TARS, IRON, XNCR, and GLPGShould you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Mirum Pharmaceuticals (MIRM), Amphastar Pharmaceuticals (AMPH), Janux Therapeutics (JANX), Apogee Therapeutics (APGE), Recursion Pharmaceuticals (RXRX), Harmony Biosciences (HRMY), Tarsus Pharmaceuticals (TARS), Disc Medicine (IRON), Xencor (XNCR), and Galapagos (GLPG). These companies are all part of the "pharmaceutical products" industry. Humacyte vs. Mirum Pharmaceuticals Amphastar Pharmaceuticals Janux Therapeutics Apogee Therapeutics Recursion Pharmaceuticals Harmony Biosciences Tarsus Pharmaceuticals Disc Medicine Xencor Galapagos Humacyte (NASDAQ:HUMA) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, community ranking, risk, institutional ownership and dividends. Which has better earnings and valuation, HUMA or MIRM? Humacyte has higher earnings, but lower revenue than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$1.57M363.95-$110.78M-$1.34-3.39Mirum Pharmaceuticals$186.37M11.90-$163.41M-$2.02-22.88 Is HUMA or MIRM more profitable? Humacyte has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -31.69%. Mirum Pharmaceuticals' return on equity of -41.22% beat Humacyte's return on equity.Company Net Margins Return on Equity Return on Assets HumacyteN/A -942.81% -93.82% Mirum Pharmaceuticals -31.69%-41.22%-14.81% Which has more volatility & risk, HUMA or MIRM? Humacyte has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Does the MarketBeat Community favor HUMA or MIRM? Mirum Pharmaceuticals received 100 more outperform votes than Humacyte when rated by MarketBeat users. Likewise, 75.58% of users gave Mirum Pharmaceuticals an outperform vote while only 63.83% of users gave Humacyte an outperform vote. CompanyUnderperformOutperformHumacyteOutperform Votes3063.83% Underperform Votes1736.17% Mirum PharmaceuticalsOutperform Votes13075.58% Underperform Votes4224.42% Do institutionals & insiders hold more shares of HUMA or MIRM? 44.7% of Humacyte shares are owned by institutional investors. 11.2% of Humacyte shares are owned by insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer HUMA or MIRM? Humacyte presently has a consensus price target of $13.00, suggesting a potential upside of 186.34%. Mirum Pharmaceuticals has a consensus price target of $57.73, suggesting a potential upside of 24.92%. Given Humacyte's higher probable upside, equities research analysts plainly believe Humacyte is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.17 Does the media favor HUMA or MIRM? In the previous week, Humacyte had 28 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 33 mentions for Humacyte and 5 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.45 beat Humacyte's score of 0.12 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 2 Very Positive mention(s) 7 Positive mention(s) 21 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMirum Pharmaceuticals beats Humacyte on 10 of the 19 factors compared between the two stocks. Ad Porter & CompanyWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HUMA vs. The Competition Export to ExcelMetricHumacyteBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$571.40M$3.10B$5.22B$8.91BDividend YieldN/A1.84%5.23%4.04%P/E Ratio-3.3914.9385.2013.34Price / Sales363.95316.581,473.6986.84Price / CashN/A175.8435.2835.09Price / Book34.924.044.914.96Net Income-$110.78M-$41.68M$117.66M$224.28M7 Day Performance2.48%6.36%2.85%1.98%1 Month Performance-15.77%5.32%1.78%9.78%1 Year Performance70.68%38.03%35.88%29.97% Humacyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HUMAHumacyte3.4361 of 5 stars$4.54+2.0%$13.00+186.3%+67.3%$571.40M$1.57M-3.39150Short Interest ↑MIRMMirum Pharmaceuticals3.909 of 5 stars$45.56-1.4%$57.73+26.7%+44.4%$2.19B$307.03M-22.88140Positive NewsAMPHAmphastar Pharmaceuticals4.9158 of 5 stars$45.11-0.2%$60.33+33.7%-20.8%$2.17B$644.40M15.061,761JANXJanux Therapeutics3.9792 of 5 stars$41.03-9.2%$67.70+65.0%+344.5%$2.15B$13.05M-35.2630APGEApogee Therapeutics2.514 of 5 stars$46.57+3.1%$83.88+80.1%+132.2%$2.10BN/A-19.1491Analyst ForecastRXRXRecursion Pharmaceuticals1.3541 of 5 stars$7.07+10.8%$9.25+30.8%+2.6%$2.03B$64.60M-4.62400Gap UpHigh Trading VolumeHRMYHarmony Biosciences4.7916 of 5 stars$35.05+1.1%$47.00+34.1%+15.3%$2.00B$681.88M16.43200Positive NewsTARSTarsus Pharmaceuticals1.4834 of 5 stars$50.64-3.5%$54.20+7.0%+217.9%$1.94B$129.62M-13.7750Positive NewsIRONDisc Medicine2.9632 of 5 stars$64.97+2.4%$85.80+32.1%+15.2%$1.93BN/A-16.2678XNCRXencor4.7409 of 5 stars$26.81+4.7%$36.50+36.1%+42.8%$1.88B$168.34M-8.00280Analyst UpgradeShort Interest ↓News CoveragePositive NewsGap UpGLPGGalapagos0.3433 of 5 stars$27.83+0.7%$30.75+10.5%-26.0%$1.83B$259.40M0.001,123Short Interest ↑ Related Companies and Tools Related Companies MIRM Competitors AMPH Competitors JANX Competitors APGE Competitors RXRX Competitors HRMY Competitors TARS Competitors IRON Competitors XNCR Competitors GLPG Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HUMA) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
